NCT03013101UnknownPhase 2
A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure
Shanghai Junshi Bioscience Co., Ltd.6 sites in 1 country128 target enrollmentStarted: December 28, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 128
- Locations
- 6
- Primary Endpoint
- Objective response rate (ORR) by RECIST 1.1 and irRECIST Objective response rate (ORR) by RECIST 1.1 and irRECIST
Study Overview
Brief Summary
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
Detailed Description
This is a multiple-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in previous routine systemic treatment. Patients are injected with JS001 with 3mg/kg every 2 weeks until disease progresses or unacceptable toxicity occurs. Response assessment is conducted by every 8 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and Female aged 18 and older are eligible;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- •Histologic diagnosis of locally advanced or metastatic melanoma, while ocular melanoma is excluded, and the overall rate of mucousal melanoma is no more than 25%.
- •Have failed at least 1 prior routine regimen for advanced disease.
- •Providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes);
- •documentary evidence of BRAF mutation status;
- •At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions) Predicted survival >=3 months;
- •Brain or meningeal metastases must be disposed with surgery or radiation, and be stable clinically for at least 3 months (prior systemic steroids was allowed, but concurrent administration of systemic steroids with the study drug is excluded).
- •Screening laboratory values must meet the following criteria（within past 14 days）:
- •hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ µL; platelets ≥ 100 x 10^3/ µL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN，creatinine clearance >50ml/min (Cockcroft-Gault equation) PT/INR, aPTT≤1.5 x ULN;
- •Without systemic steroids within past 4 weeks
- •Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 12 months after the last dose of study drug.
- •Must have read, understood, and provided written informed consent voluntarily. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
Exclusion Criteria
- •Prior treatment with anti-PD-1/PD-L1/PD-L2 antibody;
- •Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Ab or its components.
- •Prior treatment with mAb within past 4 weeks.
- •Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
- •Pregnant or nursing;
- •Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>500IU/ml)
- •History with tuberculosis;
- •Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism.
- •Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, heart block >II grade, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm).
- •Evidence with active CNS disease.
- •meningeal carcinomatosis;
- •Prior treatment with bone marrow stimulating factors，such as CSF (colony stimulating factor), EPO (erythropoietin), within past 2 weeks
- •Prior live vaccine therapy within past 4 weeks.
- •Prior major surgery within past 4 weeks (diagnostic surgery excluded).
- •Psychiatric medicines abuse without withdrawal, or history of psychiatric illness.
- •Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal cell skin cancer or carcinoma in situ of the cervix.
- •Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
Outcomes
Primary Outcomes
Objective response rate (ORR) by RECIST 1.1 and irRECIST Objective response rate (ORR) by RECIST 1.1 and irRECIST
Time Frame: 3 years
Secondary Outcomes
- Duration of response (DOR) by RECIST1.1 and irRECIST(3 years)
- Progression free survival (PFS) by RECIST1.1 and irRECIST(3 years)
- Overall survival (OS)(3 years)
- Immunogenicity of anti-PD-1 monoclonal antibody(1.5 years)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(1.5 years)
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Unknown
Phase 2
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial CarcinomaBladder Urothelial CarcinomaNCT03113266Shanghai Junshi Bioscience Co., Ltd.370
Completed
Phase 1
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid TumorsUrological CancerMelanomaNCT02836795Shanghai Junshi Bioscience Co., Ltd.35
Completed
Phase 1
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast CancerBreast CancerNCT02838823Shanghai Junshi Bioscience Co., Ltd.20
Recruiting
Phase 2
Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous CellEsophageal CancerNCT03736863The First Affiliated Hospital of Zhengzhou University125
Terminated
Phase 2
The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by SurgeryMucosal MelanomaNCT03178123Shanghai Junshi Bioscience Co., Ltd.6